

Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

Claims 1-26. (Cancelled)

27. (Currently Amended) A method of monitoring gene expression of virally encoded nucleic acid from virus infected cells within an organism, said method comprising:

(a) administering a Paramyxoviridae virus to said organism, wherein said Paramyxoviridae virus comprises a nucleic acid sequence encoding a heterologous polypeptide, wherein said nucleic acid sequence is upstream of a nucleic acid encoding a viral polypeptide, and wherein said heterologous polypeptide is released from infected cells into a biological fluid of said organism when expressed, and

(b) detecting the amount of said heterologous polypeptide in said biological fluid, thereby providing an indication of the amount of said gene expression.

28. (Previously Presented) The method of claim 27, wherein said heterologous polypeptide is biologically inactive in said organism.

29. (Previously Presented) The method of claim 27, wherein the molecular weight of said heterologous polypeptide is below 10 kilodaltons.

30. (Previously Presented) The method of claim 27, wherein said heterologous polypeptide is a tumor antigen.

31. (Previously Presented) The method of claim 27, wherein said heterologous polypeptide is a carcinoembryonic antigen.
32. (Previously Presented) The method of claim 27, wherein said heterologous polypeptide is a beta subunit of human chorionic gonadotrophin.
33. (Previously Presented) The method of claim 27, wherein said nucleic acid sequence encodes a fusion protein, wherein said fusion protein comprises said heterologous polypeptide fused to an endogenous polypeptide.
34. (Previously Presented) The method of claim 33, wherein said endogenous polypeptide is an H protein.
35. (Previously Presented) The method of claim 33, wherein said fusion protein comprises an amino acid linker sequence between said heterologous polypeptide and said endogenous polypeptide, and wherein said amino acid linker sequence comprises a protease cleavage site.
36. (Previously Presented) The method of claim 35, wherein said protease cleavage site is a furin cleavage site.
37. (Previously Presented) The method of claim 27, wherein said Paramyxoviridae virus is replication-competent.
38. (Previously Presented) The method of claim 27, wherein said Paramyxoviridae virus is selected from the group consisting of Paramyxovirus, Morbillivirus, Rubulavirus, and Pneumovirus.

39. (Previously Presented) The method of claim 27, wherein said Paramyxoviridae virus is selected from the group consisting of mumps virus, parainfluenza virus type I, parainfluenza virus type III, and Sendai virus.

40. (Previously Presented) The method of claim 27, wherein said Paramyxoviridae virus is selected from the group consisting of measles virus, rinderpest virus, phocine distemper virus, and canine distemper virus.

41. (Previously Presented) The method of claim 27, wherein said Paramyxoviridae virus is selected from the group consisting of human respiratory syncytial virus and bovine respiratory syncytial virus.

42. (Previously Presented) The method of claim 27, wherein said Paramyxoviridae virus is selected from the group consisting of Simian virus type V and Newcastle disease virus.

43. (Previously Amended) A Paramyxoviridae virus comprising a nucleic acid sequence encoding a heterologous polypeptide, wherein said Paramyxoviridae virus infects cells of an organism when administered to said organism, wherein said nucleic acid sequence is upstream of a nucleic acid encoding a viral polypeptide, and wherein said heterologous polypeptide is released from said infected cells into a biological fluid of said organism when expressed, said released heterologous polypeptide being detectable in said biological fluid, and wherein said heterologous polypeptide is biologically inactive in said organism.

44. (Cancelled)

45. (Previously Presented) The Paramyxoviridae virus of claim 43, wherein the molecular weight of said heterologous polypeptide is below 10 kilodaltons.

46. (Previously Presented) The Paramyxoviridae virus of claim 43, wherein said heterologous polypeptide is a tumor antigen.
47. (Previously Presented) The Paramyxoviridae virus of claim 43, wherein said heterologous polypeptide is a carcinoembryonic antigen.
48. (Previously Presented) The Paramyxoviridae virus of claim 43, wherein said heterologous polypeptide is a beta subunit of human chorionic gonadotrophin.
49. (Previously Presented) The Paramyxoviridae virus of claim 43, wherein said nucleic acid sequence encodes a fusion protein, wherein said fusion protein comprises said heterologous polypeptide fused to an endogenous polypeptide.
50. (Previously Presented) The Paramyxoviridae virus of claim 49, wherein said endogenous polypeptide is an H protein.
51. (Previously Presented) The Paramyxoviridae virus of claim 49, wherein said fusion protein comprises an amino acid linker sequence between said heterologous polypeptide and said endogenous polypeptide, and wherein said amino acid linker sequence comprises a protease cleavage site.
52. (Previously Presented) The Paramyxoviridae virus of claim 51, wherein said protease cleavage site is a furin cleavage site.
53. (Previously Presented) The Paramyxoviridae virus of claim 43, wherein said Paramyxoviridae virus is replication-competent.

54. (Previously Presented) The Paramyxoviridae virus of claim 43, wherein said Paramyxoviridae virus is selected from the group consisting of Paramyxovirus, Morbillivirus, Rubulavirus, and Pneumovirus.

55. (Previously Presented) The Paramyxoviridae virus of claim 43, wherein said Paramyxoviridae virus is selected from the group consisting of mumps virus, parainfluenza virus type I, parainfluenza virus type III, and Sendai virus.

56. (Previously Presented) The Paramyxoviridae virus of claim 43, wherein said Paramyxoviridae virus is selected from the group consisting of measles virus, rinderpest virus, phocine distemper virus, and canine distemper virus.

57. (Previously Presented) The Paramyxoviridae virus of claim 43, wherein said Paramyxoviridae virus is selected from the group consisting of human respiratory syncytial virus and bovine respiratory syncytial virus.

58. (Previously Presented) The Paramyxoviridae virus of claim 43, wherein said Paramyxoviridae virus is selected from the group consisting of Simian virus type V and Newcastle disease virus.